Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
272 questions in 49 reviews · Heart
current versionsNo studies 272 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mindfulness‐based interventions (MBIs) vs active comparators Clinical CVD events · people at high risk of or withcardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Transcendental meditation (TM) vs active comparators Well‐being · people at high risk of or with cardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Transcendental meditation (TM) vs active comparators Adverse events · people at high risk of or with cardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Transcendental meditation (TM) vs active comparators Smoking cessation · people at high risk of or with cardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Transcendental meditation (TM) vs non‐active comparators Clinical CVD events · people at high risk of or withcardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Transcendental meditation (TM) vs non‐active comparators Perceived stress · people at high risk of or withcardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Transcendental meditation (TM) vs non‐active comparators Well‐being · people at high risk of or withcardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Transcendental meditation (TM) vs non‐active comparators Adverse events · people at high risk of or withcardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Transcendental meditation (TM) vs non‐active comparators Smoking cessation · people at high risk of or withcardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Mindfulness‐based interventions (MBIs) vs active comparators Adverse events · people at high risk of or withcardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Continuous infusion of intravenous loop diuretics vs bolus injection of intravenous loop diuretics Cardiovascular mortality ‐ not measured · adults (aged greater than 18 years) with acute heart failure Continuous infusion versus bolus injection of loop diuretics for acute heart failure (2024) · Cochrane | no estimate extracted | NR | No studies |
Class I and/or III antiarrhythmics vs control Outcomes at > 3 to 6 months after ablation · Human trial participants undergoing ablation for atrial fibrillation Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial… (2023) · Cochrane | no estimate extracted | NR | No studies |
Class I antiarrhythmics vs control Adverse events: thromboembolic events · Human trial participants undergoing ablation for atrial fibrillation Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial… (2023) · Cochrane | no estimate extracted | NR | No studies |
Class I antiarrhythmics vs control Adverse events: myocardial infarction · Human trial participants undergoing ablation for atrial fibrillation Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial… (2023) · Cochrane | no estimate extracted | NR | No studies |
Class I antiarrhythmics vs control Adverse events: new diagnosis of heart failure · Human trial participants undergoing ablation for atrial fibrillation Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial… (2023) · Cochrane | no estimate extracted | NR | No studies |
Class I antiarrhythmics vs control All‐cause mortality · Human trial participants undergoing ablation for atrial fibrillation Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial… (2023) · Cochrane | no estimate extracted | NR | No studies |
Class III antiarrhythmics vs control Outcomes at > 3 to 6 months after ablation · Human trial participants undergoing ablation for atrial fibrillation Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial… (2023) · Cochrane | no estimate extracted | NR | No studies |
Class III antiarrhythmics vs control Adverse events: myocardial infarction · Human trial participants undergoing ablation for atrial fibrillation Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial… (2023) · Cochrane | no estimate extracted | NR | No studies |
Class III antiarrhythmics vs control Adverse events: new diagnosis of heart failure · Human trial participants undergoing ablation for atrial fibrillation Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial… (2023) · Cochrane | no estimate extracted | NR | No studies |
Class I and/or III antiarrhythmics vs control Adverse events: new diagnosis of heart failure · Human trial participants undergoing ablation for atrial fibrillation Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial… (2023) · Cochrane | no estimate extracted | NR | No studies |
Class I antiarrhythmics vs control Outcomes at > 3 to 6 months after ablation · Human trial participants undergoing ablation for atrial fibrillation Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial… (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR All‐cause hospital admission (number of events) ‐ not reported Social network interventions to support cardiac rehabilitation and secondary prevention in the management of… (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse events ‐ not reported Social network interventions to support cardiac rehabilitation and secondary prevention in the management of… (2023) · Cochrane | no estimate extracted | NR | No studies |
Effects of high‐ vs low‐added sugar consumption Cardiovascular event · Adults without diabetes or CVD High versus low‐added sugar consumption for the primary prevention of cardiovascular disease (2022) · Cochrane | no estimate extracted | NR | No studies |
Effects of high‐ vs low‐added sugar consumption All‐cause mortality · Adults without diabetes or CVD High versus low‐added sugar consumption for the primary prevention of cardiovascular disease (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Low‐carbohydrate weight‐reducing diets vs balanced‐carbohydrate weight‐reducing diets Weight loss of at least 5% at ≥ 12 months ‐ not measured · overweight and obese participants without T2DM (weight‐reducing phase followed by weight maintenance phase) Low‐carbohydrate versus balanced‐carbohydrate diets for reducing weight and cardiovascular risk (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Low‐carbohydrate weight‐reducing diets vs balanced‐carbohydrate weight‐reducing diets Cardiovascular mortality ‐ not measured · overweight and obese participants without T2DM (weight‐reducing phase followed by weight maintenance phase) Low‐carbohydrate versus balanced‐carbohydrate diets for reducing weight and cardiovascular risk (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Low‐carbohydrate weight‐reducing diets vs balanced‐carbohydrate weight‐reducing diets Constipation at 3 to < 12 months ‐ not measured · overweight and obese participants without T2DM (weight‐reducing phase followed by weight maintenance phase) Low‐carbohydrate versus balanced‐carbohydrate diets for reducing weight and cardiovascular risk (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Low‐carbohydrate weight‐reducing diets vs balanced‐carbohydrate weight‐reducing diets Cardiovascular mortality ‐ not measured · overweight and obese participants with T2DM (weight‐reducing phase only) Low‐carbohydrate versus balanced‐carbohydrate diets for reducing weight and cardiovascular risk (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Low‐carbohydrate weight‐reducing diets vs balanced‐carbohydrate weight‐reducing diets Weight loss of at least 5% at ≥ 12 months ‐ not measured · overweight and obese participants with T2DM (weight‐reducing phase followed by weight‐maintenance phase) Low‐carbohydrate versus balanced‐carbohydrate diets for reducing weight and cardiovascular risk (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Low‐carbohydrate weight‐reducing diets vs balanced‐carbohydrate weight‐reducing diets Cardiovascular mortality ‐ not measured · overweight and obese participants with T2DM (weight‐reducing phase followed by weight‐maintenance phase) Low‐carbohydrate versus balanced‐carbohydrate diets for reducing weight and cardiovascular risk (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Low‐carbohydrate weight‐reducing diets vs balanced‐carbohydrate weight‐reducing diets Constipation at 3 to < 12 months ‐ not measured · overweight and obese participants with T2DM (weight‐reducing phase followed by weight‐maintenance phase) Low‐carbohydrate versus balanced‐carbohydrate diets for reducing weight and cardiovascular risk (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Low‐carbohydrate weight‐reducing diets vs balanced‐carbohydrate weight‐reducing diets Cardiovascular mortality ‐ not measured · overweight and obese participants without T2DM (weight‐reducing phase only) Low‐carbohydrate versus balanced‐carbohydrate diets for reducing weight and cardiovascular risk (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Low‐carbohydrate weight‐reducing diets vs balanced‐carbohydrate weight‐reducing diets Change in body weight (kg) at 3 to < 12 months ‐ not measured · overweight and obese participants without T2DM (weight‐reducing phase followed by weight maintenance phase) Low‐carbohydrate versus balanced‐carbohydrate diets for reducing weight and cardiovascular risk (2022) · Cochrane | no estimate extracted | NR | No studies |
PCC vs FVIIa Adverse events · cardiac surgery for the treatment of non‐surgical bleeding Prothrombin complex concentrate in cardiac surgery for the treatment of coagulopathic bleeding (2022) · Cochrane | no estimate extracted | NR | No studies |
PCC vs standard treatment Adverse events · cardiac surgery for the treatment of non‐surgical bleeding Prothrombin complex concentrate in cardiac surgery for the treatment of coagulopathic bleeding (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Outcomes ( · health professionals from the USA and participants (“healthy volunteers from the Biobank cohort”) from the UK Effects of a gluten‐reduced or gluten‐free diet for the primary prevention of cardiovascular disease (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR All‐cause mortality · healthy normal weighted participants recruited through leaflets from Italy Effects of a gluten‐reduced or gluten‐free diet for the primary prevention of cardiovascular disease (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Non‐fatal MI · healthy normal weighted participants recruited through leaflets from Italy Effects of a gluten‐reduced or gluten‐free diet for the primary prevention of cardiovascular disease (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Stroke · healthy normal weighted participants recruited through leaflets from Italy Effects of a gluten‐reduced or gluten‐free diet for the primary prevention of cardiovascular disease (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Peripheral artery disease · healthy normal weighted participants recruited through leaflets from Italy Effects of a gluten‐reduced or gluten‐free diet for the primary prevention of cardiovascular disease (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Type 2 diabetes · healthy normal weighted participants recruited through leaflets from Italy Effects of a gluten‐reduced or gluten‐free diet for the primary prevention of cardiovascular disease (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Stroke · health professionals from the USA and participants (“healthy volunteers from the Biobank cohort”) from the UK Effects of a gluten‐reduced or gluten‐free diet for the primary prevention of cardiovascular disease (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Peripheral artery disease · health professionals from the USA and participants (“healthy volunteers from the Biobank cohort”) from the UK Effects of a gluten‐reduced or gluten‐free diet for the primary prevention of cardiovascular disease (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Systolic blood pressure · health professionals from the USA and participants (“healthy volunteers from the Biobank cohort”) from the UK Effects of a gluten‐reduced or gluten‐free diet for the primary prevention of cardiovascular disease (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Cardiovascular mortality · healthy normal weighted participants recruited through leaflets from Italy Effects of a gluten‐reduced or gluten‐free diet for the primary prevention of cardiovascular disease (2022) · Cochrane | no estimate extracted | NR | No studies |
Warfarin vs placebo or no treatment Stroke · people with heart failure in sinus rhythm Anticoagulation versus placebo for heart failure in sinus rhythm (2021) · Cochrane | no estimate extracted | NR | No studies |
Antibiotics vs placebo or no intervention Quality of life at 24±6 months · patients with coronary heart disease Antibiotics for secondary prevention of coronary heart disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Antibiotics vs placebo or no intervention Serious adverse event at maximum · patients with coronary heart disease Antibiotics for secondary prevention of coronary heart disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Antibiotics vs placebo or no intervention Quality of life at maximum · patients with coronary heart disease Antibiotics for secondary prevention of coronary heart disease (2021) · Cochrane | no estimate extracted | NR | No studies |